SNOA Valuation

Sonoma Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.820

-0.01(-0.207%)1D

Overview
Forecast
Valuation
Earnings

SNOA Relative Valuation

SNOA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNOA is overvalued; if below, it's undervalued.

Historical Valuation

Sonoma Pharmaceuticals Inc (SNOA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.46 is considered Undervalued compared with the five-year average of -0.93. The fair price of Sonoma Pharmaceuticals Inc (SNOA) is between 14.55 to 16.74 according to relative valuation methord. Compared to the current price of 4.78 USD , Sonoma Pharmaceuticals Inc is Undervalued By 67.12%.

Relative Value

Fair Zone

14.55-16.74

Current Price：4.78

67.12%

Undervalued

-4.31

Trailing

Forward

0.00

EV/EBITDA

Sonoma Pharmaceuticals Inc. (SNOA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.55. The thresholds are as follows: Strongly Undervalued below -1.37, Undervalued between -1.37 and -0.41, Fairly Valued between 1.51 and -0.41, Overvalued between 1.51 and 2.47, and Strongly Overvalued above 2.47. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.23

EV/EBIT

Sonoma Pharmaceuticals Inc. (SNOA) has a current EV/EBIT of -2.23. The 5-year average EV/EBIT is -1.06. The thresholds are as follows: Strongly Undervalued below -5.25, Undervalued between -5.25 and -3.15, Fairly Valued between 1.04 and -3.15, Overvalued between 1.04 and 3.13, and Strongly Overvalued above 3.13. The current Forward EV/EBIT of -2.23 falls within the Historic Trend Line -Fairly Valued range.

0.46

Sonoma Pharmaceuticals Inc. (SNOA) has a current PS of 0.46. The 5-year average PS is 0.29. The thresholds are as follows: Strongly Undervalued below 0.02, Undervalued between 0.02 and 0.15, Fairly Valued between 0.42 and 0.15, Overvalued between 0.42 and 0.55, and Strongly Overvalued above 0.55. The current Forward PS of 0.46 falls within the Overvalued range.

58.70

P/OCF

Sonoma Pharmaceuticals Inc. (SNOA) has a current P/OCF of 58.70. The 5-year average P/OCF is -0.31. The thresholds are as follows: Strongly Undervalued below -16.51, Undervalued between -16.51 and -8.41, Fairly Valued between 7.78 and -8.41, Overvalued between 7.78 and 15.88, and Strongly Overvalued above 15.88. The current Forward P/OCF of 58.70 falls within the Strongly Overvalued range.

0.00

P/FCF

Sonoma Pharmaceuticals Inc. (SNOA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.84. The thresholds are as follows: Strongly Undervalued below -1.05, Undervalued between -1.05 and -0.10, Fairly Valued between 1.79 and -0.10, Overvalued between 1.79 and 2.74, and Strongly Overvalued above 2.74. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Sonoma Pharmaceuticals Inc (SNOA) has a current Price-to-Book (P/B) ratio of 2.06. Compared to its 3-year average P/B ratio of 0.72 , the current P/B ratio is approximately 184.78% higher. Relative to its 5-year average P/B ratio of 1.11, the current P/B ratio is about 85.06% higher. Sonoma Pharmaceuticals Inc (SNOA) has a Forward Free Cash Flow (FCF) yield of approximately -16.40%. Compared to its 3-year average FCF yield of -92.11%, the current FCF yield is approximately -82.19% lower. Relative to its 5-year average FCF yield of -69.01% , the current FCF yield is about -76.23% lower.

1.96

P/B

Median3y

0.72

Median5y

1.11

-16.40

FCF Yield

Median3y

-92.11

Median5y

-69.01

Competitors Valuation Multiple

The average P/S ratio for SNOA's competitors is 5.55, providing a benchmark for relative valuation. Sonoma Pharmaceuticals Inc Corp (SNOA) exhibits a P/S ratio of 0.46, which is -91.71% above the industry average. Given its robust revenue growth of 18.40%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SNOA.O

Sonoma Pharmaceuticals Inc

Cyclerion Therapeutics Inc

3.92

9.21M

ADIL.O

Adial Pharmaceuticals Inc

Loss

8.37M

VYNE.O

Vyne Therapeutics Inc

Indaptus Therapeutics Inc

Performance Decomposition

Market capitalization of SNOA increased by 46.06% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.44 to -1.95.

The secondary factor is the Revenue Growth, contributed 18.40%to the performance.

Overall, the performance of SNOA in the past 1 year is driven by P/E Change. Which is more unsustainable.

18.40%

3.39M → 4.02M

Revenue Growth

-8.31%

-33.71 → -30.91

Margin Expansion

35.97%

-1.44 → -1.95

P/E Change

46.06%